Want to see KRRO full AI Analyst Report?
KRRO Stock Chart & Stats
$13.26
-$1.03(-2.68%)
At close: 4:00 PM EST
$13.26
-$1.03(-2.68%)
Day’s Range― - ―
52-Week Range$5.20 - $50.45
Previous CloseN/A
Volume28.02K
Average Volume (3M)200.27K
Market Cap
$125.02M
Enterprise Value$159.39M
Total Cash (Recent Filing)$115.04M
Total Debt (Recent Filing)$42.21M
Price to Earnings (P/E)―
Beta2.92
Next Earnings
Nov 18, 2026EPS Estimate
-1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.01
Shares Outstanding14,725,646
10 Day Avg. Volume190,258
30 Day Avg. Volume200,270
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.46
Price to Sales (P/S)11.77
P/FCF Ratio-0.95
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue66.91
Enterprise Value/Gross Profit91.97
Enterprise Value/Ebitda-2.22
Forecast
1Y Price Target
$19.33Price Target Upside45.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-5.32
Revenue Forecast (FY)$333.33K
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementMoving KRRO-121 into placebo-controlled human testing is a durable development milestone: it converts the RNA-editing platform from preclinical promise into clinical evidence generation. Safety, pharmacokinetic and early efficacy data can validate the approach and support future partnering or expansion.
Pipeline DiversificationOrphan designation for KRRO-121 and nomination of KRRO-111 broaden the development base across rare metabolic disease and AATD. This creates multiple clinical and regulatory paths, so company progress need not depend on a single candidate or indication.
Funding RunwayEnding Q2 with $137.9 million in cash and a projected runway into the second half of 2028 gives Korro time to execute trials and reach milestones without immediate financing pressure. That funding horizon supports continuity of R&D while programs mature.
Bears Say
Persistent Cash BurnCash burn of roughly $68 million on both an operating and free-cash-flow basis shows that Korro cannot yet fund development internally. Continued outflows will consume its capital base and eventually require financing, asset partnerships, or spending reductions.
Deep Operating LossesThe combination of declining, volatile revenue and deeply negative operating and net margins indicates that current activities are far from commercial scale. Until candidates generate meaningful revenue, substantial R&D spending will continue to pressure earnings and equity value.
Capital Structure RiskPast swings in the capital base, including a period of negative equity, demonstrate that Korro’s financing position has not been consistently stable. Dependence on recapitalization can dilute existing holders and constrain strategic flexibility if development costs remain high.
Korro Bio News
KRRO FAQ
What was Korro Bio’s price range in the past 12 months?
Korro Bio lowest stock price was $5.20 and its highest was $50.45 in the past 12 months.
What is Korro Bio’s market cap?
Korro Bio’s market cap is $125.02M.
When is Korro Bio’s upcoming earnings report date?
Korro Bio’s upcoming earnings report date is Nov 18, 2026 which is in 30 days.
How were Korro Bio’s earnings last quarter?
Korro Bio released its earnings results on Aug 06, 2026. The company reported -$1.07 earnings per share for the quarter, beating the consensus estimate of -$1.338 by $0.268.
Is Korro Bio overvalued?
According to Wall Street analysts Korro Bio’s price is currently Undervalued.
Does Korro Bio pay dividends?
Korro Bio does not currently pay dividends.
What is Korro Bio’s EPS estimate?
Korro Bio’s EPS estimate is -1.26.
How many shares outstanding does Korro Bio have?
Korro Bio has 14,725,646 shares outstanding.
What happened to Korro Bio’s price movement after its last earnings report?
Korro Bio reported an EPS of -$1.07 in its last earnings report, beating expectations of -$1.338. Following the earnings report the stock price went up 5.391%.
Which hedge fund is a major shareholder of Korro Bio?
Currently, no hedge funds are holding shares in KRRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Korro Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.33 (45.80% Upside)
$19.33 (45.80% Upside)
Blogger Sentiment
Neutral
KRRO Sentiment 67%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth $78.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.53%
12-Months-Change
Fundamentals
Return on Equity
-114.26%
Trailing 12-Months
Asset Growth
-9.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Korro Bio
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
KRRO Stock 12 Month Forecast
Average Price Target
$19.33
▲(45.80% Upside)
Technical Analysis
Assembly Biosciences
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Aura Biosciences Inc
―